Nivolumab vs Sorafenib in Advanced HCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Lancet Oncol 2021 Dec 13;[EPub Ahead of Print], T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, JJ Harding, P Merle, O Rosmorduc, L Wyrwicz, E Schott, SP Choo, RK Kelley, W Sieghart, E Assenat, R Zaucha, J Furuse, GK Abou-Alfa, AB El-Khoueiry, I Melero, D Begic, G Chen, J Neely, T Wisniewski, M Tschaika, B SangroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.